| Autor: |
Ruslan D. Novosiadly, Michael Kalos, Gerald E. Hall, David Surguladze, Gregory P. Donoho, Thompson N. Doman, Jason R. Manro, Frank C. Dorsey, Krishna Chodavarapu, Manisha Brahmachary, Bo Tan, Alexander Nikolayev, Kenneth D. Roth, Carmine Carpenito, Shuang Luo, Xiaodong Huang, Bonita D. Jones, Catalina M. Meyer, Yanxia Li, Andrew Capen, Darin Chin, Andreas Sonyi, Erik R. Rasmussen, Zhao Hai Lu, Nelusha Amaladas, Sandaruwan Geeganage, David A. Schaer |
| Rok vydání: |
2023 |
| Popis: |
Purpose:Combination strategies leveraging chemotherapeutic agents and immunotherapy have held the promise as a method to improve benefit for patients with cancer. However, most chemotherapies have detrimental effects on immune homeostasis and differ in their ability to induce immunogenic cell death (ICD). The approval of pemetrexed and carboplatin with anti-PD-1 (pembrolizumab) for treatment of non–small cell lung cancer represents the first approved chemotherapy and immunotherapy combination. Although the clinical data suggest a positive interaction between pemetrexed-based chemotherapy and immunotherapy, the underlying mechanism remains unknown.Experimental Design:Mouse tumor models (MC38, Colon26) and high-content biomarker studies (flow cytometry, Quantigene Plex, and nCounter gene expression analysis) were deployed to obtain insights into the mechanistic rationale behind the efficacy observed with pemetrexed/anti-PD-L1 combination. ICD in tumor cell lines was assessed by calreticulin and HMGB-1 immunoassays, and metabolic function of primary T cells was evaluated by Seahorse analysis.Results:Pemetrexed treatment alone increased T-cell activation in mouse tumors in vivo, robustly induced ICD in mouse tumor cells and exerted T-cell–intrinsic effects exemplified by augmented mitochondrial function and enhanced T-cell activation in vitro. Increased antitumor efficacy and pronounced inflamed/immune activation were observed when pemetrexed was combined with anti-PD-L1.Conclusions:Pemetrexed augments systemic intratumor immune responses through tumor intrinsic mechanisms including immunogenic cell death, T-cell–intrinsic mechanisms enhancing mitochondrial biogenesis leading to increased T-cell infiltration/activation along with modulation of innate immune pathways, which are significantly enhanced in combination with PD-1 pathway blockade.See related commentary by Buque et al., p. 6890 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
